EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

What Matters Most to Patients with NSCLC When Choosing Anticancer Treatments in China? A Best–Worst Scaling Study

Jingyi Qiao, Shimeng Liu iD, Shiyi Bao, Ying Tao, Jiaxin Zhao, Yingyao Chen iD

Patient Preference and Adherence · 2026-03 · Volume 20 · 1-11

DOI: 10.2147/ppa.s584024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Patient Preference and Adherence, 2026-03. Verfasst von Jingyi Qiao und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, Fudan University, Shanghai, People's Republic of China. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

best–worst scalingdrug therapynon–small cell lung cancerpatient preferences

Autor:innen und Institutionen

  • School of Public Health, Fudan University, Shanghai, People's Republic of China.
  • National Health Commission Key Laboratory of Health Technology Assessment (Fudan University), Shanghai, People's Republic of China.
  • Department of Teaching Management, Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China.

ORCID-Profile: Shimeng Liu, Yingyao Chen

Zitieren

APA

Qiao, J., Liu, S., Bao, S., Tao, Y., Zhao, J., & Chen, Y. (2026). What Matters Most to Patients with NSCLC When Choosing Anticancer Treatments in China? A Best–Worst Scaling Study. Patient Preference and Adherence, Volume 20, 1-11. https://doi.org/10.2147/ppa.s584024

Vancouver

Qiao J, Liu S, Bao S, Tao Y, Zhao J, Chen Y. What Matters Most to Patients with NSCLC When Choosing Anticancer Treatments in China? A Best–Worst Scaling Study. Patient Preference and Adherence. 2026;Volume 20:1-11. doi:10.2147/ppa.s584024

BibTeX
@article{Qiao2026,
  author = {Qiao, Jingyi and Liu, Shimeng and Bao, Shiyi and Tao, Ying and Zhao, Jiaxin and Chen, Yingyao},
  title = {What Matters Most to Patients with NSCLC When Choosing Anticancer Treatments in China? A Best–Worst Scaling Study},
  journal = {Patient Preference and Adherence},
  year = {2026},
  volume = {Volume 20},
  pages = {1--11},
  doi = {10.2147/ppa.s584024}
}
Kostenlos starten →